← Back to Home

A Gene Switch Left by an Ancient Virus Becomes Key to Human Embryo Model Development

A viral remnant embedded in the human genome enables early embryonic cells to activate a calcium-binding protein. New research reveals how this mechanism supports development and offers clues to how lung cancer uses the same pathway; applications in reproductive testing and cancer treatment remain to be validated.

By SURL BioNews

Development in the first few days of life may depend on a legacy left by an ancient virus. A team at the Francis Crick Institute in the United Kingdom found that a gene switch formed by this DNA is important for sustaining the growth of human embryonic stem cells and forming early embryo models. The research connects viral remnants, embryonic development, and cancer cell survival, while raising a question: how do tumors use a mechanism needed for normal development?

The study was published online in *Science Advances* on October 7. According to the paper abstract listed on LifeScience.net, the key element is a human endogenous retrovirus HERVH sequence located at 8q21.3 on chromosome 8. It can drive chimeric transcription spanning HERVH and the CALB1 gene, prompting cells to produce the calcium-binding protein calbindin, which helps buffer changes in intracellular calcium levels. The viral sequence here is a historical remnant in the genome, rather than a virus actively infecting cells.

Using gene editing, the researchers separately removed CALB1 or the HERVH switch that controls it from embryonic stem cells. The Crick Institute's account states that losing the switch impaired cell growth or caused cells to differentiate prematurely into specific cell types; the paper abstract states that CALB1 expression is critical for sustaining growth and preventing cellular senescence. These results provide functional evidence beyond previously observed gene expression.

The effects also extend to how cells form structures. Stem cells lacking calbindin could not normally form blastoids that model preimplantation blastocysts; in amnioid models that simulate amnion development after gastrulation, some cells even failed to form sac-like structures. However, these models reproduce only parts of development, so the findings cannot establish that the same changes necessarily cause implantation failure in human embryos.

Evolutionary comparisons offer another layer of explanation. The team found that the timing of this HERVH sequence's integration into the genome coincided with the onset of CALB1 expression in preimplantation embryos in the evolutionary lineage that includes humans and African apes. The host may therefore have repurposed the viral sequence as part of developmental regulation; the coincidence in timing supports this explanation but cannot, on its own, establish the extent of any reproductive advantage it conferred.

The cancer clues come from the team's earlier research on lung squamous cell carcinoma: removing calbindin inhibited cancer cell growth and triggered senescence. However, that study also found that this pathway affects inflammation signals associated with senescence, with effects varying by tumor context. The new findings therefore fill in its role in normal development, but blocking this switch cannot yet be equated directly with an effective cancer treatment.

The researchers propose that future work could test whether HERVH–CALB1 can serve as an indicator of embryo health in reproductive treatment. They could also explore cancer therapies targeting this form of calbindin, seeking to preserve the function of the conventional form in the brain and kidneys. However, this indicator has not yet been shown to predict pregnancy outcomes, and treatment selectivity and safety have not been established. These validation steps remain necessary before a developmental mechanism can become a clinical tool.

References

  1. Francis Crick Institute via Medical Xpress
  2. LifeScience.net — PubMed-imported publication record